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The clinical manifestations of hypoparathyroidism are several and variable involving most organ
system. Low serum ionized calcium level can impair several organic functions, such as neurological,
cognitive, muscular, and cardiac functions [1e4]. Neuromuscular irritability due to hypocalcemia is the
typical symptom of this disorder.
In hypoparathyroidism, the hypocalcemia can present emergently in case of anterior neck surgery
or supplemental calcium and active vitamin change or who are noncompliant with treatment. Acute
hypocalcemia states represent a medical emergency and potentially life-threatening, and the phar-
macologic intervention should be timely. In case of chronic hypocalcemia, the clinical manifestations
can bemild and often nonspecific neuromuscular symptoms. Sometime, the biochemical screening test
can reveal a status of hypocalcemia due to hypoparathyroidism not associate to severe symptom-
atology [5]. Chronic high phosphate levels and high calcium-phosphate product, resulting from the
disease itself and mostly the treatment with calcium and calcitriol, or other active vitamin D analogs
supplements, have an important role in the development of the ectopic calcifications [1]. The typical
sites of extraskeletal calcifications are: the brain (basal ganglia in particular), kidney, or joints,
eyes, skin, vasculature, and other organ systems [2e7]. In addition to the alterations of calcium and
phosphate, low serummagnesium levels can be found in these patients, and themagnesium deficit can
aggravate the signs and symptoms due to hypocalcemia [1]. The pathogenesis of other clinical features,
instead, is not yet currently well known, such as neuropsychiatric symptoms [8,9]. Table 1 summarizes
the main clinical manifestations of chronic hypoparathyroidism. The effects of hormone replacement
therapy with PTH peptides on clinical manifestations and complications are described in the review
regarding the treatment of hypoparathyroidism, included in this monothematic issue.Biochemical features
The hypoparathyroidism is typically characterized by low serum albumin-corrected calcium or
ionized calcium (below the lower limit of the normal range; respectively <8.5 mg/dl or 2.12 mmol/l)Table 1
Clinical manifestations of chronic hypoparathyroidism.
Organ/system Clinical manifestation (signs and symptoms)
Neuromuscular Tetany, muscle cramping (carpal and/or pedal spams) and twitching (Chvostek's sign,Trousseau's sign).
Laryngospasm and stridor, bronchospasm and wheezing. Fatigue, muscle weakness.
Neurological Central nervous system involvement: seizures; basal ganglia and brain calcifications (Fahr's disease),
parkinsonism or dystonia, altered mental status, impaired memory and concentration, pseudotumor
cerebri, extrapyramidal disorders, chorea.
Peripheral nervous system involvement: paresthesia and numbness (i.e. around themouth, in the fingers,
toes and circumoral region).
Psychiatric Depression, anxiety, personality disturbances.
Kidney Hypercalciuria, ectopic mineralization in the kidney (renal stones, nephrocalcinosis).
Renal function: decreased glomerular filtration rate, kidney failure.
Musculoskeletal Myopathy, elevated creatinine kinase. Normal-high BMD.
Cardiovascular Cardiac involvement: congestive heart failure (cardiomegaly, pulmonary congestion, volume overload),
chest pain, heart block.
ECG alterations: cardiac arrhythmias, prolonged QTc interval, QRS and ST segment changes suggestive of
myocardial ischemia/infarction, ventricular arrhythmias.
Respiratory Laryngospasm, bronchospasm.
Ophthalmological Papilledema, cataracts (posterior subcapsular cataracts), calcification of the cornea.
Dermatological Alopecia, scaling of the skin, deformities of the nails, onycholysis, dry skin, coarse, thin hair, pustular
psoriasis.
Gastrointestinal Constipation, abdominal cramps, steatorrhea.
Dental Altered tooth morphology, cemental hyperplasia, abnormal dentition (enamel hypoplasia), short
rounded roots, hypodontia and delay or lack of tooth eruption, possibly widening of the periodontal
ligament space.
Abbreviation: ECG: electrocardiogram.
References: [1e3,5,8,10].
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low or inappropriate, for the degree of hypocalcemia, intact parathyroid hormone (PTH) levels [3].
Since, about 50% of the total serum calcium is represented by the ionized fraction, and the remainder is
protein-bound or complexed to anions, in evaluating the degree of hypocalcemia, the corrected serum
calcium should be used, according to the following formula: corrected serum total Ca¼measured total
Ca þ [0.8  (4.0-measured serum albumin)] [5]. The measurement of free or ionized serum calcium
should be more accurate than the albumin-corrected total serum calcium concentration and is
preferred in pregnancy. However, there are several limitations to the accurate direct measurement of
ionized calcium. Sometime, the clinical utility of the ionized calcium measurement is limited by the
technical issues [10,11]. The 24-h urine calcium level may be low-normal before calcium and vitamin
d metabolites or analogs supplementation is started, and can be found increased during treatment [3].
Biochemical investigations are useful to differentiate hypoparathyroidism from other diseases
characterized by hypocalcemia, such as pseudohypoparathyroidism (PHP), a disorder due to PTH
resistance causing increased PTH levels, hypocalcaemia and hyperphosphataemia [12].
A reliable assay for measuring serum PTH is essential for diagnosis of hypoparathyroidism. Full-
length, active PTH (1e84) peptides and several forms of truncated, mostly carboxyl-terminal
fragments [especially PTH (34e84) and PTH (37e84)] represent the circulating PTH peptides [13,14].
The truncated fragments cannot activate the classic PTH1 receptor (PTH1R). In euparathyroid subjects,
the two-site immunoradiometric assay (IRMA) for PTH do not recognize large and inactive mid- and
carboxy-terminal fragments of PTH, but detect together the carboxy- and amino-terminal ends of the
molecule, that represent most circulating PTH [15e18]. This assay is the most widely used intact PTH
assay to date, and provides excellent discrimination between hypoparathyroidism and the hypocal-
cemic states of secondary hyperparathyroidism, but it not detect the majority of carboxyterminal-
terminal fragments [8]. Subsequently, a third-generation PTH assay (called also the “whole PTH” or
“biointact PTH” assay) was introduced [19]. This assay uses a C-terminal capture antibody and an
N-terminal detection antibody detecting only the extreme N-terminal region of PTH [PTH (1e6)].
However, it has not been proven to be superior in clinical practice, although studies are limited [20,21].
Magnesium (Mg2þ) deficit can be associated with impaired secretion and action of PTH [22]. Then,
in case of hypocalcemia without a known etiology, serum magnesium levels should be measured [23].
However, serumMg2þ is considered a poor marker of the body's Mg2þ stores for estimating total body
magnesium content, and more precise methods have been developed (i.e. the erythrocyte Mg2þ
concentration and the “magnesium tolerance test”), but for primarily research settings [22]. Causes of
hypomagnesemia can be divided into: decreased intake, absorption, or increased losses, and redis-
tribution [22]. Under normal circumstances, low intake of magnesium with the diet is usually not
common [24]. The most common causes of Mg2þ decreased absorption include severe diarrhea,
especially when due to laxative abuse, steatorrhea, malabsorption syndromes, and short bowel
syndrome [22]. Some drugs can determine decreased tubular reabsorption, such as diuretics, antibi-
otics, calcineurin inhibitors, and epidermal growth factor (EGF) receptor antagonists. Severe levels of
hypomagnesemia (Mg2þ levels <0.4 mmol/L) inhibit PTH secretion causing relative hypoparathy-
roidism, whereas mild decreases in Mg2þ levels to as low as 0.5 mmol/L stimulates PTH secretion [22].
The intracellular Mg2þ depletion seems to act on the a-subunits of the heterotrimeric G-proteins
associated with the CaSR inhibiting PTH. Moreover, high serum Mg2þ levels may cause hypocalcemia,
although it is usually mild in severity and asymptomatic [22].
Biochemical evaluation should include the measurement of serum concentration of 25-
hydroxyvitamin D (25OHD), as it may be of importance to a number of cellular processes and may
undergo hydroxylation to 1,25(OH)2D catalyzed by local hydroxylases in different tissues [10,25].
Renal manifestations
Physiologically, PTH increases renal tubular calcium reabsorption and urinary phosphate excretion,
therefore, in case PTH effects on tubular functions are lacking, hypercalciuria and reduced urinary
phosphate excretionwould be expected [5]. However, in chronic hypoparathyroidism, urinary calcium
and phosphate excretion may be normal in hypoparathyroid subjects not treated with calcium and
vitamin D supplements, because the filtered load of calcium tends to be lower compared to normal
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Instead, hypercalciuria often is reported in hypoparathyroid subjects treated with large amounts
of calcium and/or active vitamin D assumed in order to control of the serum calcium level [5]. High
sodium intakes may be associated with hypercalciuria [24].
The elevated calcium-phosphate product and hypercalciuria is associated to the risk of renal stones
or calcinosis, especially if large amounts of calcium and active vitamin D are needed [26]. In hypo-
parathyroid patients treated with calcium and activated vitamin D supplementation, the reported
prevalence rates of nephrocalcinosis varies between 12 and 57% [8,27]. A large Danish caseecontrol
study of patients (n ¼ 688) with post-surgical hypoparathyroidism described an increased risk of
renal complications (hazard ratio [HR], 3.67; 95% confidence interval [CI], 2.41e5.59) and of developing
kidney stones equal to 4.82 (95% CI: 2.00e11.64) in patients compared with controls [28].
The chronic standard treatment in these patients may cause also an increased risk of renal function
impairment and chronic kidney disease in the long run, particularly in those with activating CaSR
mutations [2,26]. Impaired renal function has been associated with duration of the disease, the age of
the patient, and relative time with hypercalcemia [10,26]. These renal complications are the most
serious long-term risks for patients with chronic hypoparathyroidism [2,26]. In a US large cohort of
patients (n: 120) with permanent hypoparathyroidism, (n:44) 41% of patients had an estimated
glomerular filtration rate (eGFR) of <60 ml/min/1.73 m2 (normal value: eGFR of 90 ml/min/1.73 m2),
consistent with chronic kidney disease stage 3 or higher, which was 2e17-fold higher compared to
age-adjusted normal values [26]. A Danish caseecontrol study with patients affected by nonsurgical
hypoparathyroidism (n ¼ 180) had a significantly increased risk of renal insufficiency (hazard ratio
[HR] 6.01) compared with controls [29]. Lastly, another Danish caseecontrol study with patients
affected by postsurgical hypoparathyroidism (n: 688) described that the hazard ratios for diagnosed
renal insufficiency was 3.10 (95% CI: 1.73e5.55) [28].
Bone manifestations
Physiologically, in adulthood bone mass is regulated by bone remodeling process, a tightly regu-
lated balance between bone resorption and formation. PTH has a main role in regulation of the rate of
bone remodeling, that promotes through its direct actions on osteoblasts and osteocytes and indirect
effects on osteoclasts [30]. Deficit or inappropriate level of PTH causes early a decrease in bone
resorption and then to a coupled reduction in bone formation. Afterwards, bonemass tends to increase,
since the balance between resorption and formation favors the latter [3,5]. It is still controversial,
whether these structural and dynamic skeletal abnormalities may affect bone strength or fracture risk
in hypoparathyroidism [29,31,32].
Chronic hypoparathyroidism is characterized typically by bone mineral density (BMD), as deter-
mined by dual energy x-ray absorptiometry, somewhat greater compared to age- and sex-matched
controls [31e36]. Increased BMD has been described in men and women affected by postsurgical,
autoimmune, and idiopathic hypoparathyroidism, on long-term treatment with calcium and vitamin D
supplements. Overall, BMD tends to be increased at all skeletal sites, especially at the lumbar spine [37].
Trabecular bone score (TBS), an indirect measure of bone microarchitecture, through novel grey-level
texture measurements on lumbar spine DXA images appears to be normal in hypoparathyroidism [37].
Peripheral quantitative computed tomography (pQCT) and high-resolution peripheral quantitative
computed tomography (HRpQCT), as well as direct histomorphometric analysis of bone by transiliac
bone biopsy, show that both cortical and trabecular compartments of bone are affected in these pa-
tients, including increased cortical volumetric BMD and trabecular bone volume fraction and decreased
cortical porosity [31]. By pQCT of the radius, volumetric BMD at cancellous and cortical compartments,
as well as cortical area and thickness, result greater in hypoparathyroid patients compared to controls
[37]. In hypoparathyroid subjects, the use of HRpQCT confirmed the increase in cortical volumetric
BMD but showed reduced cortical thickness, with lower cortical porosity. Trabecule were more
numerous but thinner in these patients [37]. Lastly, in another study, percutaneous iliac crest bone
biopsies of 25 subjects with hypoparathyroidism, and 25 controls were analyzed by high-resolution
microcomputed tomography. Hypoparathyroid subjects had increased cancellous bone volume,
trabecular thickness, number and connectivity. Therefore, it was confirmed that cancellous bone was
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trabecular structure [38]. Until now, as already mentioned, it is still unclear whether these structural
alterations and the dynamic skeletal abnormalities may affect bone strength or fracture risk in
hypoparathyroid patients [37].
Bone turnover markers in chronic hypoparathyroidism treated with conventional treatment
(calcium and vitamin D) are usually in the lower half of the normal range [33,38e40]. The low bone
turnover in hypoparathyroidism has been shown by histomorphometric assessment of the transiliac
bone biopsy [33,39,41], to be associated with a positive bone balance [42]. A study evaluated bone
histomorphometry in hypoparathyroid patients treated with conventional treatment, through the
analysis of iliac crest bone biopsies derived from 12 subjects (8 women and 4 men) and from 13 age-
and gender-matched normal controls [42]. This investigation showed that mean total resorption rate,
the resorption depth, and fractional formation surface were reduced, and the resorption period was
prolonged. Lastly, the quiescent period was prolonged and the activation frequency was reduced. In the
absence of PTH, vitamin D alone was not able to normalize bone resorption and bone turnover in
patients with hypoparathyroidism [42].
Fracture risk
In hypoparathyroidism, the skeletal features including low bone remodeling and high BMD, could
suggest that bone is hypermature, with an altered bone quality and, therefore, at higher risk of fracture
compared to eu-parathyroid bone [5]. However, hypoparathyroidism is a rare disorder, few data are
published regarding fracture risk in these patients, and the results are conflicting [5].
The Danish caseecontrol survey with 688 patients with postsurgical hypoparathyroidism (due to
non-malignant causes treated with standard treatment for more than 6 months) showed that hypo-
parathyroid patients did not have an increased risk of long-term overall fractures compared with con-
trols, and the risk of fractures at the upper extremities was significantly decreased in patients with
hypoparathyroidism [32]. On the other hand, in another Danish investigation with 180 subjects with
nonsurgical hypoparathyroidism, hypoparathyroid patients had a significantly increased risk of fractures
at the upper extremities, although the overall fracture risk was similar between cases and controls [29].
A small study evaluated 33 postmenopausal women underwent total thyroidectomy due to thyroid
cancer, among them, 13 subjects became hypoparathyroid. The incidence of spinal deformity (assessed
by spinal radiographs), was significantly lower inwomenwith hypoparathyroidism than in controls, and
the age-matched BMD was clearly higher [43]. On the other hand, a small study described that in 16
patients with hypoparathyroidism had an increased frequency of morphometric vertebral fractures,
compared to 17 age- and body mass index (BMI) matched normal controls, without no significant dif-
ferences in lumbar spine or total hip BMD between groups [44]. Lastly, a study evaluated vertebral
fractures, assessed by morphometry, in 104 patients affected by idiopathic hypoparathyroidism and 64
healthy controls [45]. The vertebral fractures were described in 18.3% of patients with idiopathic hy-
poparathyroidism and 4.7% of controls. Mean BMD at lumbar spine and hip were higher by 21.4% and
8.6%, respectively, in idiopathic hypoparathyroidism than in controls (P< 0.001), therefore showing that,
despite the increased BMD, the prevalence of vertebral-fractures was greater in patients with idiopathic
hypoparathyroidism (especially in postmenopausal women and those on anticonvulsant therapy) [45].
Clinical manifestations of nervous system
Central nervous system
Hypoparathyroid patients can manifest focal or generalized seizures, tonic-clonic type, caused by
severe hypocalcaemia [8]. Recently, some studies have reported a 3.8%e8% prevalence of seizures in
patients with hypoparathyroidism [26,28].
Basal ganglia calcification (BGC) is a well-known clinical complication of hypoparathyroidism
[46e49]. The reported prevalence of BGC in hypoparathyroidism varies between 52% and 74% [26,49],
whereas in the general population the prevalence of BGC is not well established, but estimates are
significantly lower (2e12.5%) [26,47]. In a cohort of 25 patients with CaSR mutations, 36% had BGC
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BGC [49]. However, in neither of these investigations therewas a systematic screening for BGC [26]. The
most common site of the central nervous system calcifications is the basal ganglia. However, these can
occur also in the grey and white matter junction, the cerebellar parenchyma, the thalamus and the
dentate nucleus. The occurrence of BGC and its progression have been associated with low calcium/
phosphorus ratio and long-standing duration of hypocalcaemic symptoms, even though, the exact
pathogenesis of these calcifications is not well known [49]. The abnormal phosphate homeostasis
seems to have a role in extraskeletal calcifications in these patients [8]. In this regard, two genes, such
as sodium-dependent phosphate transporter 2 (PIT2) and xenotropic and polytropic retrovirus re-
ceptor 1 (XPR1) encoding proteins involved in phosphate transport have been associated with familial
idiopathic basal ganglia calcification [50,51]. The possible clinical consequences of the central nervous
system calcifications are not clear. Neurological abnormalities and cognitive deficits may be patho-
physiologically related to the presence of intracranial calcification in this disorder, but the relationship
is unknown. Parkinsonism and dystonia have been described in chronic hypoparathyroidism, but with
a prevalence lower than that of BGC [26,49]. Lastly, a mutation in a type III sodium-phosphate trans-
porter leading to impaired cellular uptake of inorganic phosphatewas reported to be a cause of familial
idiopathic BGC, suggesting that extracellular accumulation of phosphate in the setting of chronic
hyperphosphatemia may contribute to BGC in hypoparathyroidism [26,51].
Peripheral nervous system
Hypocalcaemia associated to hypoparathyroidism can cause neuromuscular irritability, because
partially depolarizes the resting membrane potential of a neuron, stimulating the triggering action
potentials [52]. Paresthesia in the extremities and in the peri-oral and oral area are the manifestations
of sensory neuron irritability, as well as muscle spasms or tetany of motor neuron irritability. Muscle
spasms or tetany can vary from the carpopedal spasm, characterized by spasmic muscle contractions of
the forearm, hand, lower leg and/or feet, to life-threatening laryngospasm [53,54].
The Chvostek sign and Trousseau sign can detect an increased neuromuscular irritability [8,55].
Chvostek's sign is elicited by tapping the facial nerve in front of the ear, inducing the facial muscles on
the ipsilateral side to twitch. This causes contractions ranging from the upper lip and nose to the entire
half-face when severe and significant hypocalcemia is present. Trousseau's sign is elicited by placing a
blood pressure cuff around the arm and inflating the cuff to greater than the systolic pressure and
holding this in place for 3 min (occluding the brachial artery). The absence of blood flow and hyper-
excitability of the muscles caused by hypocalcemia determines a painful flexion of the wrist and
metacarpophalangeal joints, with extension of the distal interphalangeal and proximal interphalangeal
joints, and abduction of the fingers [56].
Neuropsychiatric manifestations
The Danish caseecontrol survey, conducted on patients with postsurgical hypoparathyroidism,
showed that hypoparathyroid patients had a significantly increased risk of hospitalization due
depression/bipolar affective disorders (HR 1.99, 95% CI 1.14e3.46) compared with age-matched and
sex-matched controls [32]. Therefore, increased risk of depression and other types of neuropsychiatric
disorders seems to be associated to postsurgical hypoparathyroidism.
An other Danish caseecontrol study described that also patients with nonsurgical hypoparathy-
roidism had a significantly increased risk of neuropsychiatric complications (HR 2.45), compared with
controls [29]. However, further studies are needed.
Ophthalmological manifestations
Cataract is a typical manifestation of hypoparathyroidism. In a caseecontrol study, the patients with
idiopathic hypoparathyroidism and cataracts, were significantly younger than patients with cataracts
without hypoparathyroidism and had evidence of more-severe posterior capsule disease and a higher
rate of anterior capsule disease [57]. In the Danish caseecontrol investigations, patients affected by
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with controls, but the risk of cataracts in patients with post-surgical hypoparathyroidism was not
significantly different compared to the general population. This studies suggest that age of onset and/or
duration of hypoparathyroidism are important contributing factors [8,28,29]. The etiology of the
cataract formation is not well known in these patients. However, some preclinical investigations
hypothesize that it may be due to chronic low serum calcium levels [58]. Recent studies have shown an
increased risk of posterior subcapsular cataracts, likely due to elevated calcium  phosphorus product
occurring in lenses in the eyes [56]. Lastly, papilledema has also be described in hypoparathyroidism
and tends to improve with normalization of serum calcium levels [8].
Cardiovascular manifestations
Cardiac arrhythmias can occur in patients with hypoparathyroidism in the presence of hypocalcaemia,
but the treatment of hypocalcaemia usually resolve promptly these symptoms [59,60]. Themost frequent
ECG alteration is the prolongation of the QTc interval, due to an increase in phase 2 of the action potential,
along with prominent U wave and T wave abnormalities [59]. Moreover, in some studies, dilated car-
diomyopathy due to hypocalcemia affecting the cardiac function, albeit rarely, has been reported [61e63].
Recently, in a cohort study of 120 patients with hypoparathyroidism, only one patient had dilated car-
diomyopathy attributed to chronic hypocalcemia [26]. Usually the improvement of cardiac dysfunction
occurs with normalization of hypocalcemia. However, a case report of a pediatric patient with severe
hypocalcaemia reported a non-reversible component in hypocalcaemia-associated dilated cardiomyop-
athy [61]. Overall, compared with controls, the Danish caseecontrol study showed that patients with
postsurgical hypoparathyroidism had no increased risk of cardiac arrhythmias (HR, 1.11; 95% CI,
0.79e1.57) or cardiovascular disease or death (HR, 0.89; 95% CI, 0.73e1.09) [28].
Muscular manifestations
Myopathy is a rare manifestation of hypoparathyroidism [64]. Only a small number of reports
regarding hypocalcemic myopathy due to hypoparathyroidism have been reported [64]. A retrospec-
tive study on 9 patients affected by idiopathic hypoparathyroidism found an inverse relationship be-
tween serum calcium and creatine phosphokinase [65]. Mild tomoderatemuscle cell degenerationwas
present in almost all patients, and the severity of changes in muscles was related to the duration of
hypocalcemia and not only to its degree [65]. Lastly, a cross-sectional study design showed that muscle
strength and maximal force production was significantly reduced in hypoparathyroid patients
compared with age matched and sex-matched controls, while the time for performing the Timed Up&
Go test and the repeated Chair stands test was significantly longer than in the hypoparathyroidism
group and the control group [66].
Dental manifestations
Dental aberrations have been described in non-surgical hypoparathyroidism with symptoms
including shortened roots, hypoplastic enamel and hypoplastic or absent teeth [67e69]. However, in
the future, further studies should be conducted for better characterizing this complication [69].
Dermatological manifestations
Hypoparathyroidism can cause also some skin manifestations. Regarding this specific clinical mani-
festation, an observational study was conducted on 21 patients mostly with postsurgical hypoparathy-
roidism [70]. Mucocutaneous manifestations were described in 76% of subjects, among these, the most
common mucocutaneous features was found in the hairs, including the loss of axillary hair, loss of pubic
hair, coarsening of body hair, and alopecia areata. Brittle and ridged nail, followed by onycholysis, ony-
chosezia, and onychomadesis were reported. The most common skin manifestation were xerotic skin in
11 patients (52.38%), followed by pellagra-like skin pigmentation, pustular psoriasis and acne form
eruption, bullous impetigo, etc. Only one case of oral candidiasis was described [70]. In several case
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with severe hypocalcaemia. This clinical manifestation improved with treatment [71,72].
Quality of life of chronic hypoparathyroidism
Several studies have assessed the quality of life in hypoparathyroidism and have showed that
hypoparathyroid patients reported reduced quality of life compared to either a normal population or
suitable controls [2,3,32,73e77]. These investigations described that hypoparathyroid patients often
complain about fatigue, muscle spasms, pain, and paresthesia, cognitive symptoms including “brain
fog” and inability to concentrate, anxiety and tendency to depression [2,3]. The etiology and the
duration of the hypoparathyroidism seem to be irrespective from reduced quality of life [5].
A German cross-sectional, controlled study, carried out with 25 women affected by postsurgical hy-
poparathyroidism compared to 25 controls (with a history of thyroid surgery but intact parathyroid
function), reported that hypoparathyroid patients had significantly higher global complaint scores with
predominant increases in thesubscalescores foranxiety,phobicanxietyandtheirphysicalequivalents [73].
An American (United States) study tested the hypothesis that surgeons and their patients could
underestimate the potential negative impact of postsurgical permanent hypoparathyroidism on quality
of life [78]. A total of 340 postsurgical patients with permanent hypoparathyroidism, 200 controls, and
102 surgeons were included in this investigation. Forty-seven percent of hypoparathyroid patients
reported that their health was “much worse” than before surgery, reporting of note interference with
social activities, paresthesias, muscle cramping, and medications. On the other hand, surgeons and
controls underestimated the negative impact of hypoparathyroidism on quality of life compared to
patients with chronic hypoparathyroidism [78]. Moreover, in United States, a web-based instrument-
conducted survey of 374 patients with hypoparathyroidism showed that hypoparathyroid patients had
a high burden of illness and experience a broad spectrum of symptoms, with a multidimensional
impact on their lives [74].
An Indian cross-sectional study showed that 62 patients with idiopathic hypoparathyroidism had
a higher proportion of neuropsychiatric and cognitive dysfunction and decreased quality of life
compared to controls [79].
Additional data on quality of life in these patients are obtained by trials with PTH treatments. In
a trail, 69 hypoparathyroid patients at baseline completed the RAND 36-Item Short Form (SF-36)
Health Survey, and scored significantly lower than the normative reference range in all 8 domains
[75]. In addition, another randomized controlled trial conducted in 62 patients with chronic
hypoparathyroidism reported that at baseline the SF-36 questionnaire showed a significantly lower
baseline score, compared to the norm-based population, at most subscales. At baseline, there were
no correlations between SF-36 measurements and BMI, age, duration of disease, or etiology of
disease [76].
Lastly, a cohort study with patients affected by nonsurgical hypoparathyroidism (57 patients) and
PHP (30 patients) reported that quality of life, evaluated with SF-36 andWHO-5Well Being Index, was
impaired equally among patients with nonsurgical hypoparathyroidism and PHP [80].
Other clinical manifestations
Many syndromic and nonsyndromic forms of hypoparathyroidism can include a broad spectrum of
signs and symptoms (see review regarding causes and pathophysiology of hypoparathyroidism), such
as dysmorphism, short stature, immunodeficiency, cardiac anomalies, skeletal abnormalities, hearing
loss, renal anomalies, and many others [1].
Pregnancy and breastfeeding
Though PTH has a negligible role in regulating calcium homeostasis in pregnancy and lactation in
womenwithout hypoparathyroidism, in case of womenwith chronic hypoparathyroidism treated with
calcium and vitamin D metabolites or analogs supplement are considered at considerable risk for
serum calcium oscillations (hypercalcemia and hypocalcaemia) when pregnant or nursing [10]. An
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stillbirth, premature labor and even neonatal death [10,81e83]. Moreover, maternal hypocalcaemia can
impair neonatal bone development and cause compensatory hyperparathyroidism in the newborn, as
well as, fractures, skeletal deformities, parathyroid hyperplasia and clinical complications, including
respiratory distress, poor feeding and hypotonia may occur [10]. On the other hand, maternal hyper-
calcemia, due to high calcium/vitamin D supplement dosage, can suppress fetal parathyroid
development causing neonatal hypocalcaemia. Therefore, pregnant and nursing women with hypo-
parathyroidism should be monitored in order to carefully adjust the therapy [10].
Diagnosis and clinical evaluation
The biochemical diagnosis of hypoparathyroidism is based on the measurement of albumin-
corrected or ionized serum calcium below the lower limits of the normal range and low, undetect-
able or inappropriate levels of PTH (measured by either a second- or third-generation immunoassay)
on at least two occasions separated by at least 2 weeks, after hypomagnesemia has been ruled out
[2,5,10]. If serummagnesium deficiency is detected, it is useful tomeasure the 24-h urinarymagnesium
level before repletion is initiated [2]. Serum phosphorus concentrations are usually high or at the upper
limit of the normal range [2]. Moreover, biochemical evaluation should be extended to the measure-
ments of 25OHD, 1,25(OH)2D, 24-h urinary calcium excretion, estimated or calculated GFR, and
eventually biochemical stone risk profile, if necessary [5,56]. In case of hypoparathyroidism after
anterior neck surgery, chronic hypoparathyroidism can be diagnosed 6 months after surgery [5].
The personal medical history should be collected in these patients, including history of anterior
neck surgery, gastrointestinal, renal, and skeletal symptoms, general quality of life, and treatments, as
well as family history [5]. Indeed, review of the patient's medical and family histories may suggest the
etiology of hypoparathyroidism, such as a personal history of neck surgery suggests that parathyroid
function may have been compromised by the surgical procedure, and a family history of hypocalcemia
can suggest a genetic cause [2]. The presence of other autoimmune endocrinopathies, such as adrenal
insufficiency or candidiasis can assume autoimmune polyendocrine syndrome type 1, or immunode-
ficiency and other congenital defects point to the DiGeorge syndrome [2]. In a patient with hypo-
parathyroidism of unknown etiology or if the patient's presentation suggests a genetic basis (i.e. young
age, family history, multiple autoimmune features) should be considered genetic counseling, genetic
testing and/or family screening [5,10].
Physical examination should be performed, focusing on: anterior neck (for signs of previous sur-
gery), signs of neuromuscular irritability, using Chvostek's, Trousseau's sign, eye examination (for
cataracts and calcifications), nail beds examination (for fungal infection), range of motion of joints
evaluation, skin manifestations such as mucosal candidiasis, vitiligo, and generalized bronzing and
signs of liver disease (suggestive of hemochromatosis, or other causes of iron overload) [2,5]. Clinical
features, including growth failure, congenital anomalies, hearing loss, or retardation suggest the
possibility of genetic disease [2].
Lastly, imaging studies should be performed, such as skull x-ray for basal ganglia and other intra-
cerebral calcifications, abdomen ultrasound for renal stones and calcifications, and dual-energy x-ray
absorptiometry for BMD measurement [5].
Clinical monitoring
Biochemical monitoring of serum ionized or albumin adjusted total calcium, phosphate, magne-
sium, creatinine levels, and eGFR, in addition to assessment of symptoms due to hypocalcaemia and
hypercalcemia at regular time intervals is recommended [5,10]. The frequency of biochemical moni-
toring depends by the extent to which a patient is stable on a given dosing regimen. In case of patients
adequately controlled, the monitoring could be performed on a yearly or twice-yearly basis, in other
cases the patients could require much more frequent monitoring [5]. When the dosage of calcium and
active vitamin D supplementations are adjusted, more frequent monitoring is suggested, also several
times per week, until a stable serum calcium concentration is documented [5]. Renal function is
monitored annually by a 24-h urine collection for calcium and creatinine excretion along with a
G. Marcucci et al. / Best Practice & Research Clinical Endocrinology & Metabolism 32 (2018) 927e939936measured creatinine clearance or eGFR. The frequency ofmonitoringmight be longer in case of stability
of renal function over time, and not associated with renal complications. The measurement of urinary
magnesium excretion can be helpful in certain situations [5]. In case of symptoms due to renal stones or
increase of serum creatinine levels renal imaging is recommended [10]. In asymptomatic patients with
a history of renal lithiasis or nephrocalcinosis, renal imaging is recommended every 5 years [5].
Frequent monitoring of patients with autosomal dominant hypocalcaemia (ADH), treated with
standard treatment, is recommended because they may be at high risk of hypercalciuria and renal
complications [10].
It is not known whether monitoring of central nervous system calcifications detected at baseline
screening is useful, since no clinical features are attributed to these calcifications [5,26,49].
Eyes examination for cortical cataracts evaluation depends on the specific clinical situation [5].
BMD monitoring also in hypoparathyroidism is recommended as per recommendations of the
International Society of Clinical Densitometry [5,84].
It is suggestedmonitoring serum ionized calcium regularly, every 2e3weeks, during pregnancy and
breastfeeding, in women treated with calcium and activated vitamin D analogs supplements [10].
Lastly, the pediatrician and/or neonatologist should be informed of maternal hypoparathyroidism [10].Summary
Hypoparathyroidism is a rare endocrine disease, and, as a consequence. It is a less studied pathology
compared to other common endocrine disorders. However, recently, some studies have been focused
on this disorder, including its clinical manifestations. The long-term consequences of chronic
hypoparathyroidism can be severe and may require the intervention of several specialists, given the
wide spectrum of clinical complications that can occur. The most severe long-term complications are
nephrocalcinosis and renal failure, markedly increased in hypoparathyroid patients treated with
chronic conventional treatment. Therefore, an adequate monitoring of renal function should be
performed. Moreover, an increased risk of seizures and calcification of the basal ganglia is clearly
documented. However, further studies should be carried out on the pathogenesis of calcifications of the
central nervous system and their clinical consequences. Regarding bone status, patients with chronic
hypoparathyroidism treated with calcium and vitamin D have higher BMD and lower bone turnover
compared to general population. Currently it is unclear if this impairs bone strength and can increase
risk of fragility fractures. A reduction of quality of life in hypoparathyroid patients treated with stan-
dard treatment has been described in several studies, but, in the future, it will be necessary to clarify
whether PTH deficiency has a role in determining central nervous system alterations. Lastly, in the
future, further studies will have to be conducted in order to clarify the pathogenesis and the epide-
miology of the clinical manifestations, and of the long-term complications associated with hypo-
parathyroidism, both in patients treated with conventional treatment and replacement therapy with
recombinant human parathyroid hormone [rhPTH (1e84)].Practice points
 The diagnosis of hypoparathyroidism is based on: hypocalcemia (albumin-corrected or
ionized serum calcium), undetectable or inappropriate levels of PTH on (at least two occa-
sions separated by at least 2 weeks). Serum phosphate levels are usually in the upper normal
or markedly elevated range (helpful but not mandatory).
 Personal and family medical history is useful to identify the cause of hypoparathyroidism.
 Genetic testing and/or family screening should be performed in case of hypoparathyroidism
of unknown etiology or suspicion of genetic basis.
 Physical examination should be performed to evaluate all possible complications.
 Biochemical assessment (bone metabolism, renal function) and target organ imaging [X-ray
(skull), renal ultrasound or computed tomography scanning and BMD by dual-energy x-ray
absorptiometry] should be performed based on the patient's clinical situation.
Research agenda
Regarding the clinical manifestations of chronic hypoparathyroidism, further studies are
necessary in the following issues:
 Pathogenesis of ectopic calcifications, and clinical consequences of brain calcifications.
 Bone quality/strength and risk of fragility fractures.
 Specific validated questionnaires for the evaluation of quality of life.
 Natural history and comorbidity.
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